The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Lukina Yu.V.

National Medical Research Center for Therapy and Preventive Medicine

Kutishenko N.P.

National Medical Research Center for Therapy and Preventive Medicine

Martsevich S.Yu.

National Medical Research Center for Therapy and Preventive Medicine

Shepel R.N.

National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of the Russia

Drapkina O.M.

National Medical Research Center for Therapy and Preventive Medicine;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Methodological recommendations: "Adherence to drug therapy in patients with chronic non-communicable diseases. Addressing the problem in a number of clinical situations"

Authors:

Lukina Yu.V., Kutishenko N.P., Martsevich S.Yu., Shepel R.N., Drapkina O.M.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2020;23(3‑2): 42‑60

Read: 19990 times


To cite this article:

Lukina YuV, Kutishenko NP, Martsevich SYu, Shepel RN, Drapkina OM. Methodological recommendations: "Adherence to drug therapy in patients with chronic non-communicable diseases. Addressing the problem in a number of clinical situations". Russian Journal of Preventive Medicine. 2020;23(3‑2):42‑60. (In Russ.)
https://doi.org/10.17116/profmed20202303242

References:

  1. World Health Organization. Adherence to long-term therapies: evidence for action. WHO Library Cataloguing-in-Publication Data. Geneva: WHO; 2003.
  2. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940-2948.
  3. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence. Its importance in cardiovascular outcomes. Curculation. 2009;119:3028-3035.
  4. Cramer J, Amonkar M, Hebborn A, Altman R. Compliance and Persistence with Bisphosphonate Dosing Regimens Among Women with Postmenopausal Osteoporosis. Curr Med Res Opin. 2005;21:9:1453-1460.
  5. Osterberg, T. Blaschke. Adherence to Medication. New England Journal of Medicine. 2005;353:487-497.
  6. Van Dulmen S, Sluijs E, van Dijk L, et al. Patient adherence to medical treatment: a review of reviews. BMC Health Service Research. 2007;7:55.
  7. Pruijm M, Schneider M-P, Burnier M. Patient adherence and the pharmacological treatment of arterial hypertension. ESH scientific letter. 2010;11(7). www.viamedical.pl
  8. Nieuwlaat R, Wilczynski N, Navarro T, et al. Intervention for enhancing medication adherence (review). Cochrane Database Syst Rev. 201420;(11):CD000011. https://doi.org/10.1002/14651858.CD000011.pub4
  9. Lukina YuV, Kutishenko NP, Martsevich SYu. Treatment adherence: modern view on a well-known issue. Cardiovascular Therapy and Prevention. 2017;16(1):91-95. (In Russ.).
  10. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence terminology and definition. Value in Health. 2008;11(1):44-47.
  11. Sung JCY, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic drugs in a lipid clinic. Am J Manag Care. 1998;4:1421-1430.
  12. Zotkin EG, Grigorieva AL., Ways to improve the effectiveness of osteoporosis therapy. Doctor. 2007;11:40-44. (In Russ.).
  13. Cooper NA, Lynch MA. Lost to follow up: a study of nonattendance at a general paediatric outpatient clinic. Arch Dis Child. 1979;54(10):765-769.
  14. Semenova YV, Kutishenko NP, Zagrebelnyy AV, et al. Influence of patients’ prehospital attendance at outpatient clinics on long-term outcomes of acute coronary syndrome: LIS-3 study. Rational Pharmacotherapy in Cardiology. 2017;13(3):363-369. (In Russ.). https://doi.org/10.20996/1819-6446-2017-13-3-363-369
  15. Martsevich SY, Navasardyan AR, Kutishenko NP, et al. The assessment of compliance to the use of new oral anticoagulants in patients with atrial fibrillation according to the PROFILE register. Rational Pharmacotherapy in Cardiology. 2014;10(6):625-630. (In Russ.).
  16. Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 2015;217047. https://doi.org/10.1155/2015/217047
  17. Laufs U, Retting-Ewen V, Bohm M. Strategies to improve drug adherence. Eur Heart J. 2011;32:264-268.
  18. Lowry KP, Dudley TK, Oddone EZ, et al. Intentional and unintentional nonadherence to antihypertensive medication. Ann Pharmacother. 2005;39(7-8):1198-1203.
  19. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the necessity — concerns frarnework. J Psychosom Res. 2008;64:41-46.
  20. Garner JB. Problems of nonadherence in cardiology and proposals to improve outcomes. Am J Cardiol. 2010;105:1495-1501.
  21. Vrijens B, De Geest S, Hughes DA, et al; ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691-705. PMID: 22486599. https://doi.org/10.1111/j.1365-2125.2012.04167
  22. De Geest S, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med. 2018;169(1):30-35. https://doi.org/10.7326/M18-0543
  23. Martsevich SY, Lukina YV, Kutishenko NP, et al. Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study). Rational Pharmacotherapy in Cardiology. 2019;15(6):864-872. (In Russ.). https://doi.org/10.20996/1819-6446-2019-15-6-864-872
  24. Levina IL. On the term «adherence (to) treatment». Bulletin of the Kuzbass scientific centre. 2013;17:51-53. (In Russ.).
  25. Martsevich SYu, Kutishenko NP, Tolpygino SN, et al. Effectiveness and safety of drug therapy in primary and secondary prevention of cardiovascular diseases Recommendations of the RSSC, 2011. Rational pharmacotherapy in cardiology. 2011;7(5):2-72. (In Russ.).
  26. Eisenberger U, Wüthrich RP, Bock A, et al. Medication adherence assessment: high accuracy of the new Ingestible Sensor System in kidney transplants. Transplantation. 2013;96(3):245-250.
  27. Straka RJ, Fish JT, Benson SR, Suh JT. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy. 1997;17(1):126-132.
  28. Trindade AJ, Morisky DE, Ehrlich AC, et al. Current practice and perception of screening for medication adherence in inflammatory bowel disease. J Clin Gastroenterol. 2011;45:878-882.
  29. Nguyen T-M, Caze AL, Cottrell N. What are validated self-report adherence scales really measuring?: a systematic review. British Journal of Clinical Pharmacology. 2014;77(3):427-445.
  30. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of self-reported measure of medical adherence. Med Care. 1986;24:67-73.
  31. Kalashnikova MF, Bondareva IB, Likhodey NV. Adherence to treatment in type 2 diabetes: definition of the concept, modern methods of evaluating patients‘ treatment. Attending physician. 2015;3:27-33. (In Russ.).
  32. Lukina YuV, Ginzburg ML, Smirnov VP, et al. Adherence to pre-hospital treatment in patients with acute coronary syndrome. Clinician. 2012;2:45-53. (In Russ.).
  33. Lukina YuV, Martsevich SYu, Kutishenko NP. Morisky-green scale: pros and cons of the universal test, work on errors. Rational Pharmacotherapy in Cardiology. 2016;12(1):63-65. (In Russ.). https://doi.org/10.20996/1819-6446-2016-12-1-63-65
  34. Pineiro F, Gil V, Donis M, Orozco D, et al. The validity of 6 indirect methods for assessing drug treatment compliance in arterial hypertension. Aten Primaria. 1997;19(7):372-374.
  35. Morisky DE, Ang A, Krousel-Wood M, Ward HD. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-354.
  36. Cuevas C, Peñate W. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting. International Journal of Clinical and Health Psychology. 2015;18(2):121-129.
  37. Sakthong P, Chabunthom R, Charoevisuthiwongs R. Psychometric properties of the Thai version of the 8-item Morisky Medication Adherence Scale in patients with type 2 diabetes. Annals of Pharmacotherapy. 2009;43:950-957.
  38. Martsevich SYu, Lukina YuV, Kutishenko NP, et al. Assessment of treatment adherence and factors affecting it in patients with stable coronary heart disease when prescribing nicorandil. Rational Pharmacotherapy in Cardiology. 2017;13(6):776-786. (In Russ.). https://doi.org/10.20996/1819-6446-2017-13-6-776-786
  39. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15(3):90-96. https://doi.org/10.1111/j.1751-7117.2000.tb00211.x
  40. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-124. https://doi.org/10.1016/s0738-3991(98)00107-4
  41. Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Meas. 2007;15(3):203-219.
  42. Fond G, Boyer L, Boucekine M. et al.Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset. Schizophr Res. 2017;182:84-89. https://doi.org/10.1016/j.schres.2016.10.023
  43. Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010;118:271-278.
  44. Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. 2011. -https://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf
  45. Sperber CM, Samarasinghe SR, Lomax GP. An upper and lower bound of the Medication Possession Ratio. Patient Prefer Adherence. 2017;11:1469-1478. Published online 2017 Aug 30. https://doi.org/10.2147/PPA.S136890
  46. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-574.
  47. Lukina YV, Kutishenko NP, Martsevich SY. The problem of adherence to the treatment in modern medicine: possibilities of solution, impact on the effectiveness of therapy and disease outcomes. Rational Pharmacotherapy in Cardiology. 2017;13(4):519-524. (In Russ.). https://doi.org/10.20996/1819-6446-2017-13-4-519-524
  48. Ageev FT, Smirnova MD, Fofanova TV. Increase adherence to therapy: «the matter of technology»? Heart failure. 2011;12:4:66. (In Russ.).
  49. Warren JR, Falster MO, Fox D, Jorm L. Factors influencing adherence in long-term use of statin. Farmacoepidemiology and drug safety. 2013. willeyonlinelibrary.com https://doi.org/10.1002/pds.3526
  50. Khokhlov AL, Lisenkova LA, Rakov AA. Analysis of the determinants of adherence to antihypertensive therapy. Good clinical practice. 2003;4:59-66. (In Russ.).
  51. Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019;10:8(1):112. https://doi.org/10.1186/s13643-019-1014-8
  52. Viana M, Laszczynska O, Mendes S, et al. Medication adherence to specific drug classes in chronic heart failure. J Manag Care Spec Pharm. 2014;20(10):1018-1026.
  53. de Vries ST, Keers JC, Visser R, et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014;76(2):134-138.
  54. Lukina YuV, Dmitrieva NA, Kutishenko NP, Kiseleva NV, Martsevich SYu. Interrelation and mutual influence of aspects of drug treatment safety and adherence to therapy in patients with cardiovascular diseases (according to the outpatient register «PROFILE»). Cardiovascular therapy and prevention. 2018;17(5):72-78. (In Russ.). https://doi.org/10.15829/1728-8800-2018-5-72-78
  55. Leporini C, De Sarro G, Russo E. Adherence to therapy and adverse drug reactions: is there a link? Expert Opin Drug Saf. 2014;13(suppl 1):41-55. https://doi.org/10.1517/14740338.2014.947260
  56. Berhe DF, Taxis K, Haaijer-Ruskamp FM, et al. Impact of adverse drug events and treatment satisfaction on patient adherence with antihypertensive medication — a study in ambulatory patients. Br J Clin Pharmacol. 2017;83(9):2107-2117. https://doi.org/10.1111/bcp.13312
  57. Jiang Y, Wickersham KE, Zhang X, et al. Side Effects, Self-Management Activities, and Adherence to Oral Anticancer Agents. Patient Preference and Adherence. 2019;13:2243-2252.
  58. Furniss L. Use of medicines in nursing homes for older people. Advances in Psychiatric Treatment. 2002;8:198-204. https://doi.org/10.1192/apt.8.3.198
  59. Sánchez Muñoz-Torrero JF, Barquilla P, Velasco R, et al. Adverse drug reactions in internal medicine units and associated risk factors. Eur J Clin Pharmacol. 2010;66(12):1257-1264. https://doi.org/10.1007/s00228-010-0866-6
  60. Suvorov AY, Martsevich SY, Kutishenko NP, et al. Evaluation of the conformity of cardiovascular therapy to current clinical guidelines in the improvement of outcomes in patients after stroke (according to the LIS-2 register). Rational Pharmacotherapy in Cardiology. 2015;11(3):247-252. (In Russ.). https://doi.org/10.20996/1819-6446-2015-11-3-247-252
  61. Malay LN, Martsevich SY, Solokhina LV, et al. Evaluation of treatment of patients with acute myocardial infarction before reference event and before discharge from the hospital: register data (Khabarovsk city). Part 2. Rational Pharmacotherapy in Cardiology. 2017;13(1):55-62. (In Russ.). https://doi.org/10.20996/1819-6446-2017-13-1-55-62
  62. Ershova AI, Meshkov AN, Yakushin SS, et al. Diagnosis and treatment of patients with severe hypercholesterolemia in real outpatient practice (according to the RECVASA registry). Rational Pharmacotherapy in Cardiology. 2014;10(6):612-616. (In Russ.). https://doi.org/10.20996/1819-6446-2014-10-6-612-616
  63. Martsevich SY, Gaisenok OV, Tripkosh SG, Lukina YV, Zagrebel’nyy AV. Real practice of statins use and its dependence on follow-up in the specialized medical centre in patients with high cardiovascular risk (according to the PROFILE register). Rational Pharmacotherapy in Cardiology. 2013;9(4):362-367. (In Russ.). https://doi.org/10.20996/1819-6446-2013-9-4-362-367
  64. Kheliya TG, Martsevich SY, Selivanova GB, Lukina YV, Drozdova LY, Voronina VP. Knowledge of modern principles of rational cardiovascular therapy in Moscow primary care physicians: survey-based assessment. Cardiovascular Therapy and Prevention. 2012;11(5):61-66. (In Russ.). https://doi.org/10.15829/1728-8800-2012-5-61-66
  65. Brow MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011;86(4):304-314.
  66. Semenova ON, Naumova EA, Schwartz YG. Adherence to long-term treatment of cardiovascular disease and non-compliance with medical recommendations: the opinion of patients and physicians by the results of focused interview. Rational Pharmacotherapy in Cardiology. 2014;10(1):55-61. (In Russ.).
  67. Suvorova KD. Aphorisms of great doctors. Hippocrates, Galen, Avicenna, Arnold of Villanova, Paracelsus. SPb.: OlmaMediaGroup/Enlightenment; 2017. (In Russ.).
  68. Kaplan NM, Victor RG, Flynn JT. Kaplan’s clinical hypertension. Eleventh edition. 2015 Wolters Kluwer — 472 pp.
  69. Improving physician adherence to clinical practice guidelines. Barriers and strategies for change. New England Healthcare Institute. 2008;55.
  70. Kleinsinger F. Working with the Noncompliant Patient. The Permanente Journal. 2010;14(1):54-60.
  71. Roter DL, Hall JA, Merisca R, Nordstrom B, et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998;36(8):1138-1161.
  72. Olshansky B. Placebo and nocebo in cardiovascular health: implications for healthcare, research, and the doctor-patient relationship. J Am Coll Cardiol. 2007;49(4):415-421.
  73. Minakov EV, Khokhlov RA, Furmenko GI, Akhmedzhanov NM. Doctor inertness as a factor disturbing effective treatment of cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2009;5(2):39-48. (In Russ).
  74. Nieuwlaat R, Wilczynski N, Navarro T, et al. Intervention for enhancing medication adherence (review). Cochrane Database Syst Rev. 2014;20(11):CD000011. https://doi.org/10.1002/14651858.CD000011.pub4
  75. Mannesse CK, Derkx FH, de Ridder MA, et al. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing. 2000;29(1):35-39.
  76. Lukina YuV, Dmitrieva NA, Zakharova AV, et al. Adverse events of drug therapy (first results of the study according to the outpatient registry PROFILE). Rational Pharmacotherapy in Cardiology. 2016;12(3):306-313. (In Russ.). https://doi.org/10.20996/1819-6446-2016-12-3-306-313
  77. Sica D, Ripley E. Low-dose fixed-combination antihypertensive therapy in hypertension. A companion to the Brenner and Rectors’ The Kidney. W.B. Saunders. 2000;497-504.
  78. Lukina YuV, Martsevich SYu. Combined therapy of arterial hypertension — a reliable way to achieve the goal. Rational Pharmacotherapy in Cardiology. 2010;6(6):859-864. (In Russ.). https://doi.org/10.20996/1819-6446-2010-6-6-859-864
  79. Lauffenburger JC, Landon JE, Fischer MA. Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study. J Gen Intern Med. 2017;32(6):619-625. https://doi.org/10.1007/s11606-016-3972-z
  80. Baumgartner A, Drame K, Geutjens S, Airaksinen M. Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review Pharmaceutics. 2020;12(2). pii: E190. https://doi.org/10.3390/pharmaceutics12020190
  81. Melikian C, White TJ, Vanderplas A. et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24(3):460-467.
  82. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes Obes Metab. 2018;20(3):497-507. https://doi.org/10.1111/dom.13108
  83. Outpatient treatment of acute respiratory viral infections (ARVI) during the COVID-19 epidemic. Methodological recommendations. Version 1 of 12.04.2020. 17 p.
  84. Norby K, Kainth K, Ganzel R. et al. Medication Adherence and Operating Room Efficiency for a Surgical Subspecialty. Fed Pract. 2017;34(3):16-19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370424/

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.